The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans

Abstract

This study assessed the pharmacodynamic and pharmacokinetic effects of the interaction between the selective norepinephrine (NE) transporter inhibitor reboxetine and 3, 4‐methylenedioxymethamphetamine (MDMA,“ecstasy”) in 16 healthy subjects. The study used …